A federal district court in Delaware adopts a U.S. Magistrate Judge’s report and recommendation dismissing in part Celsee Inc.'s motion to strike 10xGenomics Inc.'s patent infringement action. 10xGenomics holds several patents relating to its chromium product line, which provides researchers with the ability to measure gene activity on a cell-by-cell basis for large numbers of cells in a single experiment, and alleged that Celsee’s Genesis System copies 10x’s technology and business plans, makes false and misleading comparisons between Celsee’s Genesis System and 10x’s Chromium product line undercuts 10x’s pricing, and recruits 10x personnel to join Celsee. The challenged allegations support 10x’s cause of action for induced infringement, willful infringement, and its defense of non-obviousness. The court agrees with the recommendation to deny Celsee’s motion to dismiss 10x’s cause of action for false advertising under the Lanham Act. The recommendation to dismiss 10x’s causes of action for violations of the Delaware DTPA, contributory infringement, and direct infringement is adopted. The case is 10x Genomics, Inc. v. Celsee, Inc., 2019 BL 438348, D. Del., No. Civ. No. 19-862-CFC/SRF, 11/14/19.